Nephros, Inc. — Q2 2023 Form 10-Q Summary
Reporting period: Three and six months ended June 30, 2023; unaudited. Dollar amounts below are in millions unless noted. Nephros develops and sells water filtration products for medical and commercial markets. The company exited its Pathogen Detection Systems (PDS) business in 2022; PDS results are presented as discontinued operations in the 2022 comparisons.
Financial results
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Net revenue | $3.545 | $2.850 | $7.242 | $5.009 |
| Gross margin | $2.079; 59% | $1.395; 49% | $4.190; 58% | $2.448; 49% |
| Operating loss, continuing operations | $(0.435) | $(0.814) | $(0.741) | $(2.361) |
| Net loss | $(0.433) | $(1.137) | $(0.739) | $(3.104) |
| Net loss per share, attributable to Nephros shareholders | $(0.04) | $(0.12) | $(0.07) | $(0.31) |
Q2 revenue rose 24%; management attributed the increase to sales-team investment, commercial distribution partnerships, and approximately 14% growth in core programmatic business. First-half revenue rose 45%, reflecting approximately 29% core programmatic growth and an unusually large emergency-response order that added about $0.6 million in Q1. Gross margin returned to management’s stated 55%–60% target range, aided by 2022 price increases, lower shipping expense, and improved inventory management.
Q2 selling, general and administrative expense increased 19% to $2.239 million, mainly from higher bonus accruals and sales commissions; R&D expense fell 19% to $0.221 million, primarily due to SRP’s wind-down and slightly lower water-filter R&D investment. For the first half, SG&A rose 7% to $4.363 million and R&D declined 29% to $0.460 million. Q2 2022 and first-half 2022 net losses included PDS discontinued-operation losses of $0.390 million and $0.796 million, respectively.
Cash, liquidity, debt, and balance sheet
- At June 30, 2023, cash and cash equivalents were $4.060 million, current assets $7.914 million, current liabilities $1.197 million, and working capital $6.717 million. Total assets were $10.386 million and stockholders’ equity $8.655 million.
- Operating activities provided $0.502 million in cash in the first half, versus $2.869 million used in the prior-year period. The improvement reflected lower losses, higher gross profit, and a $0.920 million inventory reduction, partly offset by a $0.290 million increase in receivables. Cash increased $0.426 million from year-end 2022.
- The secured note was fully repaid by March 31, 2023; no secured-note or equipment-financing balance remained at June 30. Lease liabilities totaled approximately $0.857 million, consisting of operating and finance leases. No investing cash flows occurred in the first half of 2023.
- Inventory declined to $2.126 million from $3.153 million at year-end. The filing reports an accumulated deficit of $143.6 million.
Outlook, risks, and notable developments
- Management says recent positive operating cash flows, cost reductions, revenue growth, and available cash support its belief that funds will cover the current operating plan for at least 12 months from issuance of the financial statements. The filing also says historical losses and cash-flow trends raised substantial doubt about going concern; management believes its actions alleviate that doubt. Cash flows may fluctuate, and weaker-than-expected results could require further cuts to headcount, R&D, or other discretionary spending.
- Management expects future cash flows to trend positive over coming quarters but provides no numerical revenue or earnings guidance. Period-to-period results are described as volatile and not necessarily indicative of future performance.
- Customer concentration is notable: four customers represented 45% of Q2 revenue; three customers represented 42% of first-half revenue. The company identifies revenue growth, product liability or malfunction, regulatory compliance, financing, suppliers and distributors, and intellectual-property protection among its risks.
- The company has a 2023 minimum purchase commitment to Medica of €3.8 million (approximately $4.1 million); remaining aggregate commitments at June 30 were €3.3 million (approximately $3.6 million). The Medica license and supply agreement expires December 31, 2025, and Nephros intends to seek an extension.
- SRP, which had received FDA 510(k) clearance for its second-generation hemodiafiltration system, was dissolved in April 2023 after failing to secure a commercial partner or additional financing. Nephros received SRP’s remaining assets, including HDF intellectual property, in satisfaction of approximately $1.5 million owed to Nephros; it says it has no current HDF plans.
- Subsequent events: Nephros signed a five-year Whippany, New Jersey lease commencing September 1, 2023, with average annual payments of approximately $281,000, and subleased its Las Vegas facility for $18,000 per month through August 2024. It was moving Las Vegas operations to Whippany. The CEO retired in May; an August 9 amendment addressed the interim CFO’s compensation and options.
Important facts for investors to verify
- Whether core sales growth, excluding the one-time emergency-response order, is sustained and translates into positive operating cash flow.
- Whether gross margins remain within the stated 55%–60% target range and sales investments support profitable growth.
- Cash runway assumptions and the company’s stated ability to fund operations for at least 12 months, given its accumulated deficit and going-concern disclosure.
- Execution and financial impact of the Medica purchase commitment, license extension plans, and new facility move.
- Customer concentration, distributor and supplier dependence, and any developments affecting the dissolved SRP assets or HDF intellectual property.